Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0813
- Development stage
- Preclinical
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SIM0813 is an antibody-drug conjugate (ADC) currently under development by Shandong Simcere Medgenn, a subsidiary of Simcere Pharmaceutical. The drug is designed to target Leucine-rich repeat-containing protein 15 (LRRC15), a cell surface protein that is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor stroma and on certain mesenchymal-like tumor cells, while remaining largely absent from normal tissues. By specifically binding to LRRC15, SIM0813 facilitates the targeted delivery of a cytotoxic payload to the tumor microenvironment, aiming to exert potent anti-tumor activity and potentially overcome stroma-mediated resistance in various solid tumors.
- Other names
- SIM0813-Shandong Simcere Medgenn-LRRC15-ADCSIM-0813-Shandong Simcere Medgenn-LRRC15-ADCSIM 0813-Shandong Simcere Medgenn-LRRC15-ADC
02
Targets
LRRC15 (Leucine-rich repeat-containing protein 15)
Beyond the preview
Go deeper on SIM0813.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0813.